Search
for
Sort by
Research 151–180 of 1000+
- Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata
- Perceived Efficacy and Risks of Janus Kinase Inhibitors in Pediatric and Young Adult Alopecia Areata: A Cross‐Sectional Survey
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- Efficacy and safety of janus kinase inhibitors in the treatment of alopecia areata in children
- Hair loss disorders (alopecias)
- S116 Treatment of Concomitant Alopecia Areata and Crohn’s Disease in a Young Child With Tofacitinib: Case Report
- Treatment of lichen planopilaris with Janus kinase inhibitors
- BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
- Janus Kinase Inhibitors - A next generation treatment in Dermatology
- <i>In‐silico</i> Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its <i>In‐vitro</i> Evaluation
- Janus kinase (JAK)
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Novedades terapéuticas en tricología
- PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
- The JAK/STAT signaling pathway: from bench to clinic
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
- A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
- Alopecia Areata
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
- Under Development JAK Inhibitors for Dermatologic Diseases
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)